What are you searching for?

Sign in
Videos

Driving Trends Within Commercial & Clinical Mfg.

Robert Lee of Particle Sciences discusses emerging trends along with how to keep up

By: Kristin Brooks

Managing Editor, Contract Pharma

Robert Lee, President of Particle Sciences, a Lubrizol company, spoke with Contract Pharma at Interphex 2019. Some of the topics covered were: 

  • General trends driving the outsourcing of commercial and clinical manufacturing
  • Enhancing manufacturing capabilities to respond to these trends
  • Particle Sciences’ new nanomilling offering API screening program
  • Challenges in complex drug development, and some of the new technologies and capabilities Particle Sciences has introduced 

As Contract Pharma previously reported, Particle Sciences has also continued to invest in equipment and software by purchasing a dedicated pre-filled syringe filler for both clinical and commercial manufacturing and purchasing and validating a Waters NuGenesis Laboratory and Secure Data Management System to further enhance the compliance of laboratory systems. The new facility was built to accommodate the production of complex sterile and non-sterile finished drugs, such as injectables and lyophilized drugs. It forms part of a wider investment by Lubrizol LifeSciences to strengthen its key capabilities, focusing on new product solutions, capacity expansion and additional commercial manufacturing. 

 
 
 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics